Bioverativ Announces Results of Eloctate Study Showing High Bleed Protection and Target Joint Resolution
Note: The following is edited from a press release from Bioverativ. Read the full press release in its entirety here.
Bioverativ Inc. and Swedish Orphan Biovitrum AB announced the results of a new, post-hoc, longitudinal analysis of the pivotal Phase 3 A-LONG study and ASPIRE long-term extension study, showing that weekly prophylactic dosing with its extended half-life therapy ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein], marketed as Elocta® in Europe and the Middle East, has the potential to provide improved bleed protection over episodic treatment, resolve target joints and reduce the treatment burden associated with more frequent dosing intervals. The analysis was presented Dec. 10, 2017, in a poster session at the 59th Annual Meeting of the American Society of Hematology.
Assisting and Advocating for the Bleeding Disorders Community